Research programme: antibody drug conjugates - ADC Therapeutics

Drug Profile

Research programme: antibody drug conjugates - ADC Therapeutics

Alternative Names: ADCT 501; ADCT 601; ADCT 701

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADC Therapeutics; Cancer Research Technology
  • Developer ADC Therapeutics
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver cancer; Solid tumours

Most Recent Events

  • 01 Mar 2018 Preclinical trials in Liver cancer in United Kingdom before March 2018 (ADC Therapeutics pipeline, March 2018)
  • 27 Oct 2017 Preclinical trials in Solid tumours (Metastatic disease) in United Kingdom before October 2017 (ADC Therapeutics pipeline, October 2017)
  • 23 Oct 2017 ADC Therapeutics announces intention to submit INDs for ADCT 601 within 18 months
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top